The European Patent Office (EPO) Boards of Appeal revoked Moderna’s patent EP 3 590 949. This patent is central to Moderna's ongoing legal disputes with Pfizer and BioNTech over mRNA vaccine technology.
The ruling nullifies recent legal victories Moderna secured in German and UK national courts. The EPO based the revocation on the principle of added matter.
Regulators found that the patent's claims exceeded the information provided in the original application. Broader litigation continues as other related patent applications remain active.